Urakami 2017.

Study characteristics
Methods	Design: cross‐over RCT; randomisation ratio: 1:1
Participants	Inclusion criteria: T1DM; children; Tanner stage 1‐3; previously received a once‐daily injection of glargine at bedtime as a basal insulin regimen Exclusion criteria: — Diagnostic criteria: — Number of study centres: 1
Interventions	Intervention(s): degludec Comparator(s): glargine Duration of intervention: 24 weeks Duration of follow‐up: 24 weeks Run‐in period: —
Outcomes	Reported outcome(s) in full text of publication: hypoglycaemia, HbA1c
Study registration	Trial identifier: — Study terminated early: no
Publication details	Language of publication: English Funding: not reported Publication status: peer‐reviewed journal
Stated aim of study	Quote: "In the present study, we have compared the efficacy and safety of IGlar vs. IDeg as a basal‐bolus therapy during sequential 24‐week periods in a randomized crossover study of Japanese children with type 1 diabetes".
Notes	Study authors provided outcomes on request. No study protocol provided